Shareholder Tools

Investor Relations

Investor Relations

NASDAQ: ECYT
$4.94 + 0.16
Dec 8, 2017 at 4:00 PM ET
Intraday data provided by eSignal

Corporate Profile

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The company’s agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (PSMA) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

Press ReleasesView All

Endocyte to Present at the Jefferies 2017 London Healthcare Conference
WEST LAFAYETTE, Ind., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics f...

Read More

Endocyte Reports Third Quarter Financial Results
- Plans to Initiate Phase 3 Registration for 177Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Appli...

Read More